Biotech News

How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company

Kiora Pharmaceuticals (KPRX)Kiora PharmaceuticalsClinical readout

San Diego, California--(Newsfile Corp. - November 19, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has posted an on-demand video featuring President and CEO Brian M. Strem, Ph.D., discussing the in-licensing of KIO-401 (mitucapistat), an investigational oral calpain inhibitor for sudden vision loss caused by central retinal artery occlusion (CRAO). Click here or on the following image to view the video.

Cannot view this video? Visit:

https://d1io3yog0oux5.cloudfront.net/_4b761e6c9445bbf9c0fa832060f4ff8d/kiorapharma/files/Brian_Strem_Interview_Audiogram_re_KIO-401_with_FWS.mp4

KIO-401 has been evaluated in Phase 2 and Phase 3 CRAO studies in Japan. Building on those studies, Kiora plans to initiate a multinational Phase 3 registration trial in CRAO in 2027. The company also plans to evaluate KIO-401 in a Phase 2b trial in non-arteritic anterior ischemic optic neuropathy (NAION).

The video interview will be available for 90 days in the Events section of Kiora’s investor relations website.

About Kiora

Kiora Pharmaceuticals is a late-stage retinal therapeutics company developing small-molecule therapies targeting differentiated biological pathways implicated in vision-threatening diseases.

KIO-401 is an oral, neuroprotective calpain inhibitor in development for central retinal artery occlusion (CRAO) and non-arteritic anterior ischemic optic neuropathy (NAION), two rare, acute ischemic ophthalmic diseases with no approved pharmacologic treatments. Kiora is planning a multinational Phase 3 registration trial in CRAO and a Phase 2b clinical trial in NAION. The KIO-401 platform also has potential applications in additional ophthalmic indications, including glaucoma, where calpain-mediated injury may contribute to disease progression.

KIO-301 is a partnered Phase 2 photoswitch therapy for advanced retinitis pigmentosa. KIO-104, a DHODH inhibitor previously evaluated in the KLARITY clinical trial for retinal inflammation and fibrosis, is available for partnering or out-licensing.

For more information, visit www.kiorapharma.com .

Forward-Looking Statements

This update contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Kiora's plans for KIO-401, the targeted 2027 start of a multinational Phase 3 registration trial in CRAO and the planned Phase 2b trial in NAION.

These statements reflect management's current expectations. Actual results could differ materially due to risks and uncertainties, including whether findings from prior studies in Japan can be replicated, whether regulatory feedback changes trial design or timing, the cost and feasibility of enrolling and conducting the trials, and Kiora's ability to raise sufficient capital to fund development. Additional risks are described under "Risk Factors" in Kiora's Annual Report on Form 10-K , filed March 25, 2026, and in subsequent SEC filings.

These statements speak as of the date of this update. Kiora disclaims any obligation to update them in light of later events or new information, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324751

SOURCE Kiora Pharmaceuticals, Inc.

Released November 19, 2026

Related news

KPRXKiora Pharmaceuticals2026-10-29 11:00 EST

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

KPRXKiora Pharmaceuticals2026-08-19 11:00 EST

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

LCTXLineage Cell Therapeutics2026-11-12 21:03 EST

Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease

OCSOculis2026-10-20 06:00 EST

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

OCSOculis2026-10-29 09:39 EST

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

OCGNOcugen2026-10-06 11:02 EST

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

PRQRProQR Therapeutics2026-09-09 12:00 EST

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

OCGNOcugen2026-09-01 11:02 EST

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

EYPTEyePoint Pharmaceuticals2026-08-17 11:00 EST

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

Kiora Pharmaceuticals

Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches. KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in...

Recent company news

Stock data

Close
0.82 USD
Market cap
12.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States